Nadda shares President Murmu's call for stronger ICMR malaria push
Synopsis
Key Takeaways
India's drive to eliminate malaria by 2030 got a presidential endorsement on Tuesday, November 17, 2026, as Union Health Minister J. P. Nadda amplified remarks by President Draupadi Murmu crediting ICMR for anchoring the country's fight against its most stubborn infectious diseases — and urging the council to take on dengue next.
Sharing the President's statement on X, Nadda quoted Rashtrapati Bhavan as saying: 'The National Institute of Malaria Research has contributed to the development of an indigenous malaria vaccine being developed by the National Institute of Health Research, Bhubaneswar. This will strengthen the Malaria Elimination Mission. ICMR has made significant contributions against TB, leprosy, kala-azar and COVID-19. I am confident the institute will also play an effective role in the diagnosis and control of diseases like dengue.'What the indigenous malaria vaccine means for India's 2030 target
India's National Framework for Malaria Elimination 2016–2030 set a hard deadline: zero indigenous cases by the end of the decade. Progress has been real but uneven — the country still carries a significant share of South-East Asia's malaria burden, with transmission hotspots concentrated in Odisha, Jharkhand, Chhattisgarh and parts of the northeast.
An indigenously developed vaccine, if it clears clinical trials, would shift that calculus dramatically. It would reduce dependence on imported immunisation tools, cut procurement costs, and — critically — allow India to calibrate the product to the specific Plasmodium strains most prevalent on the subcontinent. The involvement of the National Institute of Health Research in Bhubaneswar — located at the heart of one of the country's highest-burden states, Odisha — also signals that the science is being done close to the ground-level problem.
ICMR's track record: from leprosy to COVID-19
ICMR, the apex biomedical research body under the Ministry of Health and Family Welfare, has been the backbone of India's elimination programmes for decades. Its institutes contributed surveillance tools, diagnostics and drug-efficacy data to the national campaigns against tuberculosis, leprosy, and kala-azar — three diseases India has officially targeted for elimination. During the COVID-19 pandemic, ICMR was at the centre of test-kit validation, sero-survey design and domestic vaccine co-development.
President Murmu's remarks place dengue as the next frontier. Unlike malaria or kala-azar, dengue has no nationally deployed vaccine in India, and the country reports among the highest dengue caseloads in the world every monsoon season. A direct presidential call for ICMR to sharpen its diagnostics and control tools for the disease is a signal the government wants institutional bandwidth directed there.
The Health Minister's amplification — and what it signals politically
J. P. Nadda, who holds charge of both the Ministry of Health and Family Welfare and the Ministry of Chemicals and Fertilizers, sharing the President's statement underlines the alignment between Rashtrapati Bhavan and the Union government on the public-health agenda. It is also a reaffirmation of the broader 'Aatmanirbhar Bharat' logic applied to vaccine science: build it here, test it here, deploy it here.
The post arrives as India heads deeper into the second half of its malaria-elimination timeline, with roughly four years remaining before the 2030 deadline. Indigenous vaccine development, expanded ICMR mandates for vector-borne diseases, and sustained investment in institutes like the one in Bhubaneswar will all be tested against that clock.
Four years is not a long runway. And the President just made sure everyone knows it.